The Future of Health Technology Assessment (HTA) in Greece: Trends and Predictions

By Staff Writer

October 22, 2023

Greek Healthcare System

The Greek healthcare system is a unique blend of both public and private sectors. The National Organisation for the Provision of Health Services (EOPYY), established in 2011, is the sole purchaser of healthcare services for patients covered by the publicly financed National Health System (ESY). The Ministry of Health (MoH) is responsible for planning and regulating the ESY, and setting up regional health authorities (YPEs) that carry out extensive healthcare planning, organisation, and provision.

The introduction of the HTA framework in Greece in 2018 was a significant step forward towards evidence-based resource allocation decisions. It has improved patient access to innovative therapies at affordable prices and in a timely manner. Since its establishment, a significant improvement in the performance of the HTA process has been observed. The backlog of medicinal products has decreased, as well as the time of HTA clinical assessment.

However, the current HTA process in Greece does not include medical devices. This creates significant uncertainty for the providers of medical devices and pharmaceutical companies. A Committee for the Negotiation of Medical Devices’ Fees and Prices does exist, but it is not involved in the assessment of new technologies. It only negotiates the prices of technologies that either already exist in the market or are imported through ad hoc decisions.

There is strong consensus that the creation of a national decisive and legally binding HTA organisation, which will be independent of the MoH, both administratively and financially, might be more credible and effective. Another next step would be the inclusion of assessment and negotiation procedures for medical devices under an HTA organisation. This would help streamline the process and increase efficiency in the healthcare system.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.